NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

In the policy document you quoted (UK Government’s “New Approach to Ensure Regulators and Regulation Support Growth”, updated 31 March 2025), it explicitly says:

“From July 2025, new regulations will allow the safe development of highly personalised and critical medicines to be manufactured and supplied for patients in hospitals or in their homes, at the point of care.”

That’s not just a vague future promise — it's a fixed launch date for MHRA's new regulatory framework for point-of-care manufacturing of innovative medicines.